{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:33:18Z","timestamp":1793068398966,"version":"4.5.0"},"reference-count":72,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2024,5,3]]},"DOI":"10.1080\/13543784.2024.2348062","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T08:24:25Z","timestamp":1714379065000},"page":"441-449","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Novel investigational drugs for alopecia areata and future perspectives"],"prefix":"10.1080","volume":"33","author":[{"given":"Ivana","family":"Chim","sequence":"first","affiliation":[{"name":"Sinclair Dermatology, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragini","family":"Ghiya","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney D","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology, Melbourne, Australia"},{"name":"Department of Medicine, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Eisman","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14126"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12941"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.6085"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000530076"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.047"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00711-3"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955035"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes14071362"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S376096"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00764-w"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00222-2"},{"key":"e_1_3_4_15_1","unstructured":"Sunpharma.com [Internet]. Late breaking phase 3 data at AAD 2023 show oral investigational medicine deuruxolitinib significantly improved scalp hair regrowth in Alopecia Areata. Mumbai (India): Sun Pharmaceutical Industries Limited; 2023 Mar 18 [cited 2023 Nov 1]. Available from: https:\/\/sunpharma.com\/wp-content\/uploads\/2023\/03\/Press-Relaese-Late-Breaking-Phase-3-Data-at-AAD-2023-Show-Oral-Investigational-Medicine-Deuruxolitinib.pdf"},{"key":"e_1_3_4_16_1","unstructured":"U.S Food and Drug Administration [Internet]. FDA approves first systemic treatment for Alopecia Areata. Silver Spring (MD): United States government; 2022 Jun 13 [cited 2023 Oct 23]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-systemic-treatment-alopecia-areata"},{"key":"e_1_3_4_17_1","unstructured":"European Medicines Agency [Internet]. Amsterdam (NL): European Medicines Agency c1995-2023. Olumiant (baricitinib); 2020 Oct 27 [cited 2023 Oct 23]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant#authorisation-details-section"},{"key":"e_1_3_4_18_1","unstructured":"Therapeutic Goods Administration [Internet]. Olumiant (Eli Lilly Australia Pty Ltd). Canberra (ACT): Australian Government Department of Health and Aged Care; 2023 May 15 [cited 2023 Oct 23]. Available from: https:\/\/www.tga.gov.au\/resources\/prescription-medicines-registrations\/olumiant-eli-lilly-australia-pty-ltd-1"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad253"},{"key":"e_1_3_4_20_1","unstructured":"clinicaltrials.gov. A study of baricitinib (LY3009104) in children from 6 years to less than 18 years of age with Alopecia Areata (BRAVE-AA-PEDS). Bethesda (MD): National Library of Medicine; 2023 Feb 10 [cited 2023 Nov 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05723198"},{"key":"e_1_3_4_21_1","unstructured":"pfizer.com. FDA approves Pfizer\u2019s LITFULO\u2122 (ritlecitinib) for adults and adolescents with severe Alopecia Areata. (NY) (NY): Pfizer Inc; 2023 Jun 23 [cited 2023 Oct 30]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and"},{"key":"e_1_3_4_22_1","unstructured":"European Medicines Agency [Internet]. Amsterdam (NL): European Medicines Agency c1995-2023 litfulo (ritlecitinib); 2023 Sep 18 [cited 2023 Oct 23]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/litfulo"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S334727"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.036"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.050"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.260"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15937"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15657"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000494613"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.040"},{"key":"e_1_3_4_32_1","unstructured":"clinicaltrials.gov [Internet]. A study to evaluate efficacy and safety of deucravacitinib in participants with Alopecia Areata.Bethesda (MD): National Library of Medicine; 2022 Sep 23 [cited 2023 Oct 31]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05556265?intr=Deucravacitinib&cond=Alopecia%20Areata&rank=1"},{"key":"e_1_3_4_33_1","unstructured":"clinicaltrials.gov [Internet]. A study to evaluate the safety and effectiveness of upadacitinib tablets in adult and adolescent participants with severe Alopecia Areata (up-AA). Bethesda (MD): National Library of Medicine; 2023 Aug 22 [cited 2023 Oct 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06012240?cond=Alopecia%20Areata&intr=Upadacitinib&rank=1"},{"key":"e_1_3_4_34_1","unstructured":"AbbVie News Centre [Internet]. RINVOQ\u00ae (upadacitinib) receives its sixth U.S. FDA approval. North Chicago (IL): AbbVie Inc; 2022 Oct 21 [cited 2023 Oct 28]. Available from: https:\/\/news.abbvie.com\/news\/press-releases\/rinvoq-upadacitinib-receives-its-sixth-us-fda-approval.htm"},{"key":"e_1_3_4_35_1","unstructured":"European Medicines Agency. Amsterdam (NL): European Medicines Agency c1995-2023. Rinvoq (upadacitinib); 2019 Dec 18 [cited 2023 Oct 31]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.056"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.001"},{"key":"e_1_3_4_38_1","unstructured":"clinicaltrials.gov [Internet]. Study to evaluate the safety and efficacy of Jaktinib in adults with Alopecia Areata (AA). Bethesda (MD): National Library of Medicine; 2021 Nov 20 [cited 2023 Oct 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05051761?term=ZGJAK018&rank=2"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.02.063"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.016"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02336-0"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.043"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.06.029"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2021.02.003"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000512"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.10.010"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.03.019"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15071"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-018-1823-y"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-018-1853-5"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.08.015"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17010"},{"key":"e_1_3_4_53_1","unstructured":"clinicaltrials.gov. Study of Daxdilimab for the treatment of moderate-to-severe Alopecia Areata. Bethesda (MD): National Library of Medicine; 2022 Apr 11 [cited 2023 Oct 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05368103?intr=daxdilimab&rank=2"},{"key":"e_1_3_4_54_1","unstructured":"clinicaltrials.gov. A study to evaluate the efficacy and safety of Rosnilimab (ANB030) in treatment of subjects with moderate-to-severe Alopecia Areata (AZURE). Bethesda (MD): National Library of Medicine; 2022 Jan 11 [cited 2023 Oct 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05205070?cond=Alopecia%20Areata&intr=Rosnilimab&rank=1"},{"key":"e_1_3_4_55_1","unstructured":"clinicaltrials.gov. Safety and efficacy of oral etrasimod in adult participants with moderate-to-severe Alopecia Areata. Bethesda (MD): National Library of Medicine; 2020 Sep 15 [cited 2023 Oct 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04556734?cond=Alopecia%20Areata&intr=etrasimod&rank=1"},{"key":"e_1_3_4_56_1","unstructured":"clinicaltrials.gov. Study of EQ101 in adult subjects with moderate to severe Alopecia Areata. Bethesda (MD): National Library of Medicine; 2022 Oct 13 [cited 2023 Oct 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05589610?cond=Alopecia%20Areata&intr=EQ101&rank=1"},{"key":"e_1_3_4_57_1","unstructured":"clinicaltrials.gov. Randomized double-blind placebo-controlled phase 2a proof-of-concept trial of ADX-914 phase 2a trial for the treatment of severe Alopecia Areata (SIGNAL-AA). Bethesda (MD): National Library of Medicine; 2023 Aug 15 [cited 2023 Oct 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06018428?cond=Alopecia%20Areata&intr=ADX-914&rank=1"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijt.ijt_59_19"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2020.3749"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.034"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-018-1876-y"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15489"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3830"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15062"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.03.041"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.080"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13812"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.5935\/scd1984-8773.20201211512"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081829"},{"key":"e_1_3_4_70_1","unstructured":"U.S Food and Drug Administration. Janus kinase (JAK) inhibitors: drug safety communication - FDA requires warnings about increased risk of serious heart-related events cancer blood clots and death. Silver Spring (MD): United States government; 2021 Sep 1 [cited 2023 Oct 25]. Available from: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19426"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.20351"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00892-5"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2024.2348062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T08:44:20Z","timestamp":1718700260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2024.2348062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,3]]}},"alternative-id":["10.1080\/13543784.2024.2348062"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2024.2348062","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}